左西孟旦注射液治疗充血性心力衰竭的疗效评价  

Efficacy of Levosimendan in Congestive Heart Failure

作　　者：苏丽军[1] 白小涓[1] 王标[1] 杨光[1] 张海山[1] 齐国先[1] 

机构地区：[1]中国医科大学附属第一医院循环内科,沈阳110001

出　　处：《中国医科大学学报》2008年第2期263-266,共4页Journal of China Medical University

摘　　要：目的评价左西孟旦(Levosimendan)治疗充血性心力衰竭(CHF)临床疗效及不良反应。方法选取缺血性心肌病和扩张型心肌病病人50例(超声心动图证实左室射血分数≤40%),其中实验组26例,给予左西孟旦治疗;对照组24例,给予多巴酚丁胺治疗。观察两组用药前后生命体征、呼吸困难程度、射血分数及血生化指标的变化。结果用药前两组比较,其基本生命指标无统计学差异。用药后,部分病人与用药前做了自身对照,左西孟旦在提高射血分数和每搏量指标方面有显著差异(P<0.05)。用药有关的不良反应实验组9例(占34.62%),停药2例;对照组6例(占25.00%),停药4例。结论左西孟旦可引起CHF病人呼吸困难程度下降,全身状况改善,射血分数提高。Objective To evaluate the etficacy and safety of levosimendan in the treatment of congestive heart failure（CHF）. Methods A randomized,open,control clinical trial was conducted in 50 patients with CHF. 26 of the patients were treated with levosimendan in the trial group, and 24 were treated with dobutamine in the control group. Vital signs, dyspnea, eject fraction（EF） and blood biochemical index before and after drug administration were observed. Results There were significant differences in the increase of the EF and SV between the trial group and control group,but no significant differences were found in diastolic blood pressure,heart rate, Side effects were found in 9 patients of the trial group and 6 patients of the control group. Conclusion Levosimendan is effective in treating CHF and it can relieve dyspnea, improve the general condition and increase EF.

关 键 词：左西孟旦 多巴酚丁胺 充血性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]